雷迪帕韦-索非布韦联合利巴韦林治疗丙型肝炎肝硬化患者的疗效分析 : = Effect Analysis of Ledipasvir-Sofosbuvir Combined with Ribavirin in the Treatment of Hepatitis c Cirrhosis
目的分析雷迪帕韦-索非布韦联合利巴韦林治疗丙型肝炎肝硬化患者的疗效。方法选取我院88例丙型肝炎肝硬化患者(2016年12月～2018年8月),简单随机化分组,各44例。对照组给予常规治疗,在此基础上,实验组给予雷迪帕韦-索非布韦+利巴韦林,均治疗6个月。观察2组不良反应,对比治疗3个月后、治疗6个月后HCV-RNA转阴率及肝功能指标[天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)]。结果与对照组比较,治疗3个月后、6个月后实验组HCV-RNA转阴率较高(P<0.05);与对照组比较,治疗3个月后、6个月后实验组AST、TBIL水平较低(P<0.05);实验组不良反应发生率15.91%与对照组11.36%比较,差异无统计学意义(P>0.05)。结论丙型肝炎肝硬化采用雷迪帕韦-索非布韦联合利巴韦林治疗,可提高HCV-RNA转阴率,改善肾功能,且安全性较高。.
Objective To analyze the efficacy of ledipasvir-sofosbuvir combined with ribavirin in the treatment of patients with hepatitis C cirrhosis. Methods 88 patients with hepatitis C cirrhosis from December 2016 to August 2018 were enrolled in our hospital. They were randomly randomized into two groups of each 44 patients.The control group was given conventional treatment,the experimental group was given radipavir-sofobuvir +ribavirin for 6 months. The adverse reactions between the two groups were observed,and the HCV-RNA negative rate and liver function indexes(AST and TBIL) were compared after 3 months of treatment and 6 months after treatment. Results Compared with the control group,the HCV-RNA conversion rate was higher in the experimental group after 3 months and 6 months after treatment(P<0.05). Compared with the control group,the experimental group AST after 3 months and 6 months after treatment. The level of TBIL was lower(P<0.05). The incidence of adverse reactions in the experimental group was that of 15.91% compared with 11.36% in the control group. The difference was not statistically significant(P>0.05). Conclusion Hepatitis C cirrhosis with radifivirsofobuvir combined with ribavirin can improve the HCV-RNA negative rate,improve renal function and being safe..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-12-31 2019 |
|---|---|
| Erschienen: |
2019-12-31 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
Kou an wei sheng kong zhi - (2019), 06 vom: 31. Dez., Seite 37-39 Original Letters: Enthalten in 口岸卫生控制 (DE-600)2991407-3 (DE-600)2991407-3 天津市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Effect Analysis of Ledipasvir-Sofosbuvir Combined with Ribavirin in the Treatment of Hepatitis c Cirrhosis |
|---|
| Beteiligte Personen: |
武宏宾 [VerfasserIn] |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Themen: |
丙型肝炎 |
|---|
| Anmerkungen: |
Author info:Wu HongBin;Shangshui County People's Hospital |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ645967696 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ645967696 | ||
| 003 | DE-627 | ||
| 005 | 20230121123825.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230104s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ645967696 | ||
| 035 | |a (SBB-XA)CAJ_KAWS201906012 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R512.63 |2 clc | ||
| 084 | |a R575.2 |2 clc | ||
| 100 | 0 | |a 武宏宾 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 雷迪帕韦-索非布韦联合利巴韦林治疗丙型肝炎肝硬化患者的疗效分析 |b = Effect Analysis of Ledipasvir-Sofosbuvir Combined with Ribavirin in the Treatment of Hepatitis c Cirrhosis |
| 246 | 3 | 1 | |a Effect Analysis of Ledipasvir-Sofosbuvir Combined with Ribavirin in the Treatment of Hepatitis c Cirrhosis |
| 264 | 1 | |c 2019-12-31 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:Wu HongBin;Shangshui County People's Hospital | ||
| 520 | |a 目的分析雷迪帕韦-索非布韦联合利巴韦林治疗丙型肝炎肝硬化患者的疗效。方法选取我院88例丙型肝炎肝硬化患者(2016年12月～2018年8月),简单随机化分组,各44例。对照组给予常规治疗,在此基础上,实验组给予雷迪帕韦-索非布韦+利巴韦林,均治疗6个月。观察2组不良反应,对比治疗3个月后、治疗6个月后HCV-RNA转阴率及肝功能指标[天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)]。结果与对照组比较,治疗3个月后、6个月后实验组HCV-RNA转阴率较高(P<0.05);与对照组比较,治疗3个月后、6个月后实验组AST、TBIL水平较低(P<0.05);实验组不良反应发生率15.91%与对照组11.36%比较,差异无统计学意义(P>0.05)。结论丙型肝炎肝硬化采用雷迪帕韦-索非布韦联合利巴韦林治疗,可提高HCV-RNA转阴率,改善肾功能,且安全性较高。 | ||
| 520 | |a Objective To analyze the efficacy of ledipasvir-sofosbuvir combined with ribavirin in the treatment of patients with hepatitis C cirrhosis. Methods 88 patients with hepatitis C cirrhosis from December 2016 to August 2018 were enrolled in our hospital. They were randomly randomized into two groups of each 44 patients.The control group was given conventional treatment,the experimental group was given radipavir-sofobuvir +ribavirin for 6 months. The adverse reactions between the two groups were observed,and the HCV-RNA negative rate and liver function indexes(AST and TBIL) were compared after 3 months of treatment and 6 months after treatment. Results Compared with the control group,the HCV-RNA conversion rate was higher in the experimental group after 3 months and 6 months after treatment(P<0.05). Compared with the control group,the experimental group AST after 3 months and 6 months after treatment. The level of TBIL was lower(P<0.05). The incidence of adverse reactions in the experimental group was that of 15.91% compared with 11.36% in the control group. The difference was not statistically significant(P>0.05). Conclusion Hepatitis C cirrhosis with radifivirsofobuvir combined with ribavirin can improve the HCV-RNA negative rate,improve renal function and being safe. | ||
| 610 | 2 | 4 | |a 河南省商水县人民医院 |
| 650 | 4 | |a 传染病 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a 消化系及腹部疾病 | |
| 650 | 4 | |a Infectious Disease | |
| 650 | 4 | |a Digestive System Disease | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 丙型肝炎 | |
| 650 | 4 | |a 肝硬化 | |
| 650 | 4 | |a 雷迪帕韦-索非布韦 | |
| 650 | 4 | |a 利巴韦林 | |
| 650 | 4 | |a Hepatitis C | |
| 650 | 4 | |a Cirrhosis | |
| 650 | 4 | |a Ledipasvir-Sofosbuvir | |
| 650 | 4 | |a Ribavirin | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Kou an wei sheng kong zhi |d Tian jin shi, 1996 |g (2019), 06 vom: 31. Dez., Seite 37-39 |h Online-Ressource |w (DE-627)CAJ172591295 |w (DE-600)2991407-3 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:06 |g day:31 |g month:12 |g pages:37-39 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KAWS201906012 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KAWS201906012 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 口岸卫生控制 |d 天津市 |h Online-Ressource |w (DE-627)CAJ172591295 |w (DE-600)2991407-3 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 06 |b 31 |c 12 |h 37-39 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 06 |b 31 |c 12 |h 37-39 | ||
| 980 | |2 11 |1 01 |x 0001 |b 665472420 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 04-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=KAWS201906012 | ||